Press & Publications

Your question, our answer

2024

 

Press release: Cold season 2024/2025 - Rapid spread due to Oktoberfest and Mikrogen’s contribution to diagnostics


Munich, October 2024 – RSV season has picked up speed early this year in Germany. In addition to the well-known increase in respiratory diseases in the colder months of the year, major events such as the Munich Oktoberfest are mainly to blame for the rapid spread of infections this year. Especially Mycoplasma pneumoniae and Bordetella pertussis (whooping cough) are showing a worrying increase in cases. This development calls for rapid and targeted diagnostic action in order to prevent uncontrolled spread and to ensure effective treatment.


The Munich Oktoberfest, which attracts millions of people from all over the world every year, has once again proven to be a hotspot for the spread of respiratory diseases. Huge crowds of people in a confined space provide ideal conditions for the transmission of pathogens, including mycoplasma and bordetella. Initial reports from health authorities have already confirmed an increase in reported infections that can be traced back to Oktoberfest. Young adults, who are often not sufficiently vaccinated against whooping cough, are particularly vulnerable.

 

Mikrogen‘s contribution to the management of the 2024/2025 cold season
Mikrogen Diagnostik GmbH, a leading company in the field of infection diagnostics, plays a crucial role in combating the current cold season. With a wide range of diagnostic tests, Mikrogen offers reliable and precise tools to detect and differentiate respiratory diseases at an early stage. Particularly noteworthy are specific tests for identifying Mycoplasma pneumoniae and Bordetella pertussis/parapertussis, which are increasingly being used this season.


Thanks to Mikrogen‘s highly specific PCR diagnostics, doctors and laboratories can land on a clear diagnosis within a very short time. This is crucial for initiating targeted therapies and limiting the spread of pathogens. The tests are easy to use, fast and highly sensitive, making them an indispensable tool in the current infection situation.


Early detection and targeted measures
With the rapid spread of respiratory illnesses due to Oktoberfest, rapid and conclusive diagnostics are crucial. Mikrogen ensures laboratories across Germany are ideally prepared for this cold season and can help minimize the health impact. Especially during this challenging time, when influenza, mycoplasma and whooping cough can occur simultaneously, Mikrogen offers solutions that enable rapid differentiation of the pathogens and thus support targeted treatment. Mikrogen also emphasizes the importance of preventive measures such as vaccination, especially against whooping cough, to control the spread of Bordetella. The combination of vaccination programs and state-of-the-art diagnostics offers the best chance of successfully overcoming the current cold season.

 

Read the press release

 

Contact for further inquiries:
Mikrogen Diagnostik GmbH
Press Department
Email: presse@mikrogen.de
Phone: +49 (0) 89 54801-0
Website: www.mikrogen.de

The future of laboratory diagnostics: Competence meets innovation

From Lyme borreliosis to STIs and hepatitis E– laboratory diagnostics are becoming increasingly important across all indications and pathogens. With state-ofthe-art testing methods, laboratories these days lay the foundation for effective customised therapies, preventing the spread of infectious diseases and making an important contribution to public health care.

At the 18th Mikrogen Forum, eight speakers gave us invaluable insights into their work and presented compelling perspectives for diagnostics in their respective fields.
We would like to thank everyone who attended and are pleased to present a summary of the presentations below. → Read the full summary of our Mikrogen Forum

It was a great pleasure for both parties when the certificate was officially presented to us by mdc (medical device certification GmbH), represented by Harald Rentschler and Laura Schüer.
This certification is a milestone in our commitment to quality assurance and product safety.
 
As a leading company in the field of in-vitro diagnostics, we are committed to meeting the highest standards for the quality and reliability of our products.
IVDR certification is further proof that continuous quality assurance is an integral part of our corporate culture.
 
Since the end of May IVDR certification will be mandatory for manufacturers of in-vitro diagnostics throughout Europe.
We have started to adapt our processes to the strict requirements of the IVDR much earlier. During regular audits, we check in particular the suitability and quality of all elements that contribute to the quality of our products. The result: we are IVDR certified since 10.01.2024!

We at Mikrogen are proud to be able to make our contribution to the safety and health of patients worldwide. The IVDR certification is a further step on our way to ensure and continuously improve our quality.